Board Stats: 417 members / 1445 guests (24 hrs)

Dendreon Corporation

To request your Free Account, send an email to admin@investorvillage.com.
REMINDER: Special Lifetime Offer option holders - you have until 5/31 to exercise. Send a PM to Admin for payment instructions.
Have a Safe Memorial Day Weekend.

DNDN / Message Board / Read Message

BOARD

GROUPS

NEWS

a_technical_1

AMMASS

Anaxos

bbildman

beerbierbeer

BEZAGRE

bull trout

caseystarman

ced17

chandler

charolais1966

crescentmotor

DendLONG

emrssf

filosofer989

flyer_21144

goamofo

grandpatb

green228

ICE

intuitive_investor

investor737

iyonwin

japanjimmyd

jerzee

JustOnce

Lawsoot

medchal

mij3000

ming the merciless

mugabe abu

mwhunt_99

nerdseeksblonde

Nighttrain

no1coalking

nopec2001

okos_fiu

orion_gambler

pccure

pgh27106

retiredend99

ridge runner

roachmotell66

rynotheknife

SaulK

shamblinthru

TFRingo

The_HJW

tnl

tsb

uraniumisit

zbg2007

zino

View This Message Only All Messages in Topic Single Thread Only Author List Message List

My DNDN Ignore List

Keyword
Subject

Between			and
Rec'd By

Authored By
Minimum Recs

return to message board, top of board

Msg 351393 of 438881 at 5/20/2010 10:27:28 PM by

The following message was updated on 5/20/2010 10:28:31 PM.

I thought we were going to get a surprise Zibotentan phase III data abstract....

This is only phase I data so I guess they are holding it?? Who knows.

Phase I study of the specific endothelin A receptor antagonist zibotentan (ZD4054) combined with docetaxel in patients with metastatic castration-resistant prostate cancer: Assessment of efficacy, pain, and safety.

http://abstract.asco.org/AbstView_74_49761.html

e-mail to a friend

printer-friendly

add to library

| More

Recs: 1 | Views: 239

return to message board, top of board


	About Us • Contact Us • Follow Us on Twitter • Members Directory • Help • Advertise Not a member yet? What are you waiting for? Join Now Want to contribute? Support InvestorVillage by donating © 2003-2010 Investorvillage.com. All rights reserved. User Agreement